Terns Pharmaceuticals, Inc.
TERN
$2.92
-$0.13-4.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.40% | -46.77% | 2.53% | -3.41% | 6.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.86% | -24.85% | 20.69% | 5.34% | 42.96% |
| Operating Income | -7.86% | 24.85% | -20.69% | -5.34% | -42.96% |
| Income Before Tax | -3.76% | 26.34% | -27.22% | -3.76% | -35.26% |
| Income Tax Expenses | -18.37% | 6.90% | -15.28% | 61.67% | -84.59% |
| Earnings from Continuing Operations | -3.71% | 26.28% | -27.05% | -3.93% | -32.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.71% | 26.28% | -27.05% | -3.93% | -32.85% |
| EBIT | -7.86% | 24.85% | -20.69% | -5.34% | -42.96% |
| EBITDA | -7.91% | 24.93% | -20.69% | -5.33% | -43.33% |
| EPS Basic | 17.79% | 32.23% | -21.73% | 2.53% | -0.45% |
| Normalized Basic EPS | 17.77% | 32.28% | -21.91% | 2.70% | -2.26% |
| EPS Diluted | 17.79% | 32.23% | -21.73% | 2.53% | -0.45% |
| Normalized Diluted EPS | 17.77% | 32.28% | -21.91% | 2.70% | -2.26% |
| Average Basic Shares Outstanding | 26.14% | 8.79% | 4.34% | 6.62% | 32.24% |
| Average Diluted Shares Outstanding | 26.14% | 8.79% | 4.34% | 6.62% | 32.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |